论文部分内容阅读
巴曲酶注射液作为缺血性血管疾病的治疗药物应用于日本和中国的临床已有十余年的时间,临床应用充分证实巴曲酶注射液是安全有效的。 1995年,国内的陈清棠教授执笔的多中心、前瞻、随机、对照开放实验在发病72小时内给予巴曲酶治疗,治疗过程中未发现明显不良反应,治疗10天巴曲酶组有效牢为82.6％,对照组为59％。之后,于1998～1999年由陈清棠教授负责进行了严格的RCT实验进一步验证了巴曲酶注射液的临床效果和安全性。 白求恩医科大学附属第一医院冯加纯教授对于近几年的300余篇文章
Batroxobin injection as a therapeutic agent for ischemic vascular disease has been applied to clinical trials in Japan and China for more than ten years. The clinical application of Batroxobin injection is safe and effective. In 1995, the domestic multi-center, prospective, randomized and controlled open-ended trial conducted by Professor Chen Qingtang gave batroxobin within 72 hours after onset. No obvious adverse reactions were found during the course of treatment. The effective jail for batroxobin group for 10 days was 82.6 %, Control group was 59%. After that, from 1998 to 1999, Professor Chen Qingtang conducted a rigorous RCT experiment to further verify the clinical efficacy and safety of batroxobin injection. Feng Bachun, the First Affiliated Hospital of Bethune Medical University, has published more than 300 articles in recent years